2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC
  5. Drug-Linker Conjugates for ADC Isoform

Drug-Linker Conjugates for ADC

 

Drug-Linker Conjugates for ADC Related Products (149):

Cat. No. Product Name Effect Purity
  • HY-131057
    Mc-VC-PAB-SN38
    Mc-VC-PAB-SN38 consists a cleavable ADC linker (Mc-VC-PAB) and a DNA topoisomerase I inhibitor (SN38). Mc-VC-PAB-SN38 can be used in the synthesis of antibody-drug conjugates (ADCs).
  • HY-153180
    PB038
    		98.99%
    PB038 is a Drug-liker containing a PEG unit and a cleavable linker attached to Exatecan.
  • HY-126687
    Mal-PEG4-VC-PAB-DMEA-PNU-159682
    Mal-PEG4-VC-PAB-DMEA-PNU-159682, a agent-linker conjugate for ADC, consists the ADC linker Mal-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682.
  • HY-139441
    DM21
    		99.92%
    DM21 is a conjugate of a cleavable ADC agent and a linker (ADC linker) used in the synthesis of antibody-drug conjugates (ADCs).
  • HY-148820
    Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT
    		98.43%
    Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT (Formula V) is a agent-linker conjugate that composed of a potent topoisomerase I inhibitor and a linker to make antibody agent conjugate (ADC).
  • HY-164239
    NH2-PEG3-VC-PAB-MMAE
    		99.10%
    NH2-PEG3-VC-PAB-MMAE is a drug-linker conjugate for ADC, consisting of a cleavable ADC linker (NH2-PEG3-VC-PAB) and a potent tubulin inhibitor Monomethyl auristatin E (MMAE) (HY-15162). NH2-PEG3-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs).
  • HY-164088
    DBM-C5-VC-PAB-MMAE
    DBM-C5-VC-PAB-MMAE (Compound 3a) is a Drug-Linker conjugate for ADC. DBM-C5-VC-PAB-MMAE is composed of a linker C5-VC-PAB with a maleimide group DBM and an ADC toxin MMAE (HY-15162).
  • HY-160899A
    Thailanstatin A cyclohexane diamine formic
    Thailanstatin A cyclohexane diamine formic is an analog of Spliceostatin (HY-16466). Thailanstatin A cyclohexane diamine formic inhibits proliferations of cells N87 (IC50 is 0.33 μM), BT474 (IC50 is 0.34 μM), MDA-MB-361-DYT2 (IC50 is 0.88 μM) and MDA-MB-468 (IC50 is 0.27 μM). Thailanstatin A cyclohexane diamine formic is used as a drug-linker conjugate for ADC molecule.
  • HY-136170
    MC-SN38
    		99.32%
    MC-SN38 is a agent-linker conjugate composed of a potent microtubule-disrupting agent SN38 and a non-cleavable MC linker to make antibody agent conjugate (ADC). SN-38, an active metabolite of the Topoisomerase I inhibitor Irinotecan, inhibits DNA synthesis and causes frequent DNA single-strand breaks.
  • HY-139642
    Mal-(CH2)5-Val-Cit-PAB-Eribulin
    		99.82%
    Mal-(CH2)5-Val-Cit-PAB-Eribulin is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB.
  • HY-153013
    SN38-COOH
    		98.85%
    SN38-COOH is used for the synthesis of antibody-drug conjugates (ADCs). SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis.
  • HY-153892
    Gly-Mal-GGFG-Deruxtecan 2-hydroxypropanamide
    		99.79%
    Gly-Mal-GGFG-Deruxtecan 2-hydroxy propionamide is a camptothecin-deriver and can be used as a drug linker for ADC.
  • HY-148426
    OSu-PEG4-VC-PAB-MMAE
    		98.19%
    OSu-PEG4-VC-PAB-MMAE involves in GDP-FAmP4MMAE (Monomethylauristatin E) synthesis, which is for GDP label via site-specific conjugation.
  • HY-130812
    Gemcitabine-O-Si(di-iso)-O-Mc
    		98.79%
    Gemcitabine-O-Si(di-iso)-O-Mc is a agent-linker conjugate for ADC with potent antitumor activity by using Gemcitabine (a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent; HY-17026), linked via the ADC linker.
  • HY-132250
    MCC-DM1
    		99.52%
    MCC-DM1 is a agent-Linker Conjugates for ADC such as Anti-CD22-MCC-DM1. MCC-DM1 can be detected in rat and human plasma, feces, and other tissues.
  • HY-148057
    TCO-PEG4-VC-PAB-MMAE
    		99.30%
    TCO-PEG4-VC-PAB-MMAE is a agent-linker conjugate for ADC. TCO-PEG4-VC-PAB-MMAE contains a cleavable ADC linker (TCO-PEG4-VC-PA) and a potent tubulin inhibitor MMAE (HY-15162). TCO-PEG4-VC-PAB-MMAE is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.
  • HY-154915
    MC-EVCit-PAB-MMAE
    		99.04%
    MC-EVCit-PAB-MMAE (Linker-Payload 11) is a drug-linker conjugates for ADC. MC-EVCit-PAB-MMAE contains the ADCs linker (MC-EVCit-PAB) and a potent tubulin polymerization inhibitor MMAE (HY-15162).
  • HY-15575G
    VcMMAE (GMP)
    VcMMAE (MC-Val-Cit-PAB-MMAE) (GMP) is VcMMAE (HY-15575) produced by using GMP guidelines. VcMMAE is a drug-linker conjugate for ADC.
  • HY-153032
    Val-Ala-PAB-MMAE
    Val-Ala-PAB-MMAE is a Drug-Linker Conjugate for ADC, consisting of ADC linker (Val-Ala-PAB) and MMAE. MMAE is an effective inhibitor of tubulin.
  • HY-153263
    (Aminooxy)acetamide-Val-Cit-PAB-MMAE
    (Aminooxy)acetamide-Val-Cit-PAB-MMAE (MMAE 5) is an intermediate used in the synthetic preparation of drug-linker conjugates for ADC. (Aminooxy)acetamide-Val-Cit-PAB-MMAE is conjugated to polyamide via oxime bond formation to form MMAE polyamide conjugate. Then MMAE polyamide conjugate can be conjugated to Trastuzumab, to make ADC.